Monoclonal antibodies (K3-2F2 and K3-4C8) raised against hepatitis A virus were used to develop a solid-phase radioimmunoassay and enzyme-linked immunosorbent assay for the detection of hepatitis A virus and antibody. Assays with this pair of monoclonal antibodies were compared in parallel with similarly constructed solid-phase radioimmunoassays and enzyme-linked immunosorbent assays in which human polyclonal serum was used. The monoclonal antibody assay proved to be more sensitive for the detection of hepatitis A virus from fecal specimens as well as for anti-hepatitis A virus immunoglobulin G (IgG) and IgM in sera.
Hepatitis A virus (HAV) is a 27-to 32-nm virus (10) whose biophysical and biochemical characteristics (8) have resulted in its classification as a member of the genus enterovirus (13) within the family Picornaviridae (5) .
Recently, three monoclonal antibodies (K2-4F2, K3-2F2, K3-4C8) against hepatitis A virus were developed (21) . These antibodies were selected to react with the major surface antigens of HAV and appeared to recognize closely related (antigenically similar or sterically associated) antigenic determinants (21) . In this paper, we report the use of two of these antibodies in the development of a solid-phase radioimmunoassay (SPRIA) and an enzyme-linked immunosorbent assay (ELISA) for the detection of HAV and its class-specific immunoglobulin G (IgG) and IgM antibodies.
MATERIALS AND METHODS
Patients. Six groups of subjects were studied: 25 patients with acute hepatitis A, 20 patients with a prior history of hepatitis A, 20 patients with acute hepatitis B, 10 patients with non-A non-B hepatitis, 10 patients with diseases other than acute viral hepatitis, and 20 healthy laboratory staff members.
All patients were admitted to Fairfield Hospital for Communicable Diseases, Melbourne, Australia, between June 1980 and January 1984. Sera from each subject and at least one fecal specimen from each of the 25 patients with acute hepatitis A were collected and stored at -20°C until tested. In all cases, the diagnoses were made by specialist physicians on the basis of clinical assessment aided by laboratory tests.
Diagnostic criteria. A patient was considered to have hepatitis A if HAV was detected in fecal specimens collected during acute illness (19, 20) , if a rising titer of anti-HAV was demonstrated between paired sera (18) , if hepatitis Aspecific IgM was detected in acute-phase sera (17, 18) , or if a combination of these was observed. Commercial assays were used to test all specimens to define the six groups of * Corresponding author. patients and to determine the relative sensitivity of the in-house assays. Tests for HAV were performed by SPRIA (19) and ELISA (Hepanostika HAV; Organon Teknika, BV Broxtel, Holland). Tests for anti-HAV and hepatitis Aspecific IgM were performed by SPRIA (HAVAB and HAVAB M; Abbott Laboratories, North Chicago, Ill.). All sera from patients with acute and past hepatitis A infections were also tested for hepatitis B surface antigen by SPRIA (Ausria II-125; Abbott Laboratories) and found to be negative.
A diagnosis of hepatitis B was established by the detection of hepatitis B surface antigen in acute, but not in convalescent, sera. All positive results were confirmed by specific neutralization tests (14) . A diagnosis of non-A non-B hepatitis was made by absence of serological evidence of infection with HAV, hepatitis B virus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus (11) .
Fecal extracts. Fecal extracts were prepared as 10% (wt/vol) suspensions in phosphate-buffered saline (PBS; pH 7.4) containing 0.1% (wt/vol) sodium azide. The extracts were partially purified by differential centrifugation and solvent extraction (6, 7) before testing.
Reagents: (i) coating antibody. Monoclonal antibodies K3-2F2 and K3-4C8 were produced in ascites fluid from mice and purified by protein A-Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala, Sweden) as described previously (21) . K3-2F2 was used as the coating (capture) antibody, and K3-4C8 was used as the detector antibody. Human anti-HAV was prepared from the serum of an adult female 4 months after admission to the hospital with serologically confirmed hepatitis A. The IgG component was purified from 5.0 ml of serum by precipitation with ammonium sulfate and ion-exchange chromatography on DEAE-cellulose (DE-52, Whatman, Maidstone, England) as described by Purcell et al. (24, 25) . Purified mouse and human anti-HAV IgG were stored at -20°C. Anti-human IgM (mu chain specific) and anti-human IgG (gamma chain specific) prepared in rabbits were obtained commercially (Dakopaths a/s, Copenhagen F, Denmark).
(ii) HAAg. Reagent HAV antigen (HAAg) was prepared 120 COULEPIS ET AL.
from a pool of six fecal specimens known to contain HAV by SPRIA and immune electron microscopy (20, 25) . After preparation of a 20% (wt/vol) fecal extract in PBS, HAAg was purified by differential centrifugation, solvent extraction, and finally agarose gel filtration on Sepharose C1-2B (Pharmacia) as described previously (6, 16 6 .0 with 1 N NaOH, and then 9 parts of this solution were added to 1 part of 0.05% (vol/vol) H202, and the mixture was used immediately (29) . Alkaline phosphatase colorigenic substrate was prepared by dissolving 100 mg of p-nitrophenol phosphate (Sigma) in 100 ml of 0.1 M diethanolamine buffer (pH 9.8) containing 0.5 mM MgCl2 (4) (24, 25) .
Determination of ELISA cutoff point. The results of the ELISA assay (both colorigenic and fluorigenic) were expressed as a P/N value, where P was the reading of the sample and N was the mean reading of the three negative control samples tested at the same dilution as the test sample. By using the N value, the individual P/N value for each negative control serum was calculated. The mean plus 3 standard deviations of these three P/N values was used as the cutoff point to signify the lowest level at which HAV, anti-HAV IgG, and anti-HAV IgM were present (32) . RESULTS (i) Detection of HAV. Of the 25 fecal specimens collected from the group of patients with acute hepatitis A infection, HAV was detected in the same 9 specimens by all the tests being evaluated (SPRIA with human and monoclonal antibody reagents, ELISA with human and monoclonal antibody reagents, and the commercial Hepanostika HAV assay). Although there were no false-positive or -negative results, the monoclonal antibody assays had much lower background values than the human reagents, which led to lower cutoff values for the assays. In the SPRIAs, the mean negative control value for the monoclonal antibody assay was 72 cpm compared with 265 for the human antibody assay. The ranges of P/N values for the positive and negative specimens in the monoclonal antibody assays were 6.5 to 30.9 and 0.6 to 1.4, respectively, compared with 3.1 to 20.7 and 1.5 to 2.0 for the human antibody assay. Similarly, in the ELISAs, the higher background reading obtained with the human reagents resulted in higher cutoff values (Table 1) .
Endpoint titrations were performed on nine positive samples by SPRIA and ELISA. The titers obtained with the monoclonal antibody assays were at least four times higher than those obtained with assays with human antibody (Table  2) . Within both assay groups, the SPRIA and fluorigenic ELISA were of equal sensitivity and were twofold more sensitive than the colorigenic ELISAs. A similar pattern of sensitivity was obtained between the various assays when cell culture strains of HAV were tested.
(Hi) Detection of anti-HAV IgG and anti-HAV-specific IgM. Detection of anti-HAV IgG and anti-HAV-specific IgM by SPRIA and ELISA in the six groups of subjects investigated by the various monoclonal antibody assays was consistent with the results of human reagents and commercial kits. Anti-HAV IgG was detected in all 25 acute-phase sera from HAV-infected patients and in all of the 20 sera from patients with past HAV infection. Of the 20 sera from acute hepatitis B virus infection, 10 were positive for anti-HAV IgG, and of the 10 sera from acute non-A non-B hepatitis, 4 had detectable levels of anti-HAV IgG. Among the 10 sera from acute infections other than hepatitis, 4 had anti-HAV IgG, and 6 of the 20 sera from healthy laboratory staff were positive for anti-HAV IgG. Anti-HAV IgM was detected in all of the 25 acute-phase sera from HAV-infected patients and in none of the sera of patients from the other five groups.
The monoclonal antibody assays had lower background readings than those in which human reagents were used, and consequently, the calculated cutoff values were lower. In the SPRIAs for anti-HAV IgG detection (Table 3 ), the mean negative control value for the monoclonal antibody assay was 179 cpm compared with 672 for the assay with human antibody. The ranges of P/N values for the positive and negative anti-HAV IgG specimens in the assay with monoclonal antibody were 28.6 to 72.3 and 0.7 to 1.4, respectively, compared with 4.5 to 12.9 and 0.8 to 2.0 for the assay with human antibody.
In the anti-HAV IgM assay with monoclonal antibody (Table 3) (12) . The sensitivity and specificity of tests with monoclonal antibodies appear to be equal to or better than those for SPRIA with polyclonal serum (12, 30) and not as sensitive as those for FA with polyclonal serum (23) . The purpose of this study was to determine the value of two monoclonal antibodies directed against HAV as diagnostic reagents in SPRIA and ELISA. In this study, the monoclonal antibody assays for the detection of HAV, anti-HAV IgG, and anti-HAV IgM performed better than commercially available tests and the parallel assays in which human reagents were used. Endpoint titration of the markers of HAV infection by the various assays showed that those in which monoclonal antibodies were used were more sensitive than both the commercial tests and the parallel assays in which human reagents were used (Tables 2 and 4 The monoclonal antibody assays for the detection of HAV could also be used to monitor the growth of different strains of HAV in cell cultures. Furthermore, cell culture-derived HAAg proved to be as effective as HAAg derived from feces in the monoclonal antibody assays for the detection of anti-HAV IgG and IgM. The combination of monoclonal antibodies and cell culture-derived HAV provides diagnostic reagents free of the inherent problems associated with reagents of human or primate origin.
In general, the study has shown that anti-HAV mono- clonal antibodies can be used as diagnostic reagents in both SPRIA and ELISA for the detection of infection with HAV. These reagents perform better than polyclonal reagents in terms of sensitivity. They share, with other monoclonal antibodies, the advantages of production in unlimited quantities of antibodies which require complete characterization only once. They should prove valuable as diagnostic reagents, free from the problems of quality and quantity which affect primate or human convalescent serum. Further exploitation of these antibodies in HAV immunoassays can be expected in the future.
